Cholecystokinin-8 vs PT-141
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | PT-141 |
|---|---|---|
| Category | Endocrine Peptides | Performance |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 1143.2 Da | 1,025.2 Da |
| Half-Life | 1-2 min | ~2.7 hours |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | 7 |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | 1.75 mg |
| Route | endogenous secretion|research IV/SC | SC |
| Purity | ≥98% | — |
| Studies Count | 97 | 178 |
| Research Status | Endogenous | FDA Approved |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.